Interview with Robert Karl, Managing Director, MSD Russia
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Address: MSD Pharmaceuticals, Shabolovka 10, 119049, Moscow,Russia
Tel: +7 495 916-7100
Web: http://www.merck.com/index.html
About MSD
Today’s MSD is a global healthcare leader working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. For more information, visit www.msd.com. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.
About MSD in Russia
In Russia, MSD is committed of developing innovative, first-in-class products, improving health and saving lives of Russian citizens. MSD in Russia is dedicated to science and scientific excellence, focusing on clinical research activities in the country. MSD products have been available in Russia for many years. In Russia, the company was recently renamed into MSD Pharmaceuticals LLC.
About MSD in Emerging Markets
In the Emerging Markets, MSD is currently ranked #5 by market share among multinational companies (IMS Health 2009); this ranking includes Asia Pacific, Latin America, Eastern Europe, Middle East and Africa. For MSD, Emerging Markets are defined as the following regions and countries: Asia Pacific, China, Latin America, Brazil, Eastern Europe and Middle East and Africa, including Russia.
MSD’s current portfolio and R&D focus are complementary to important disease areas with pressing public health issues in Emerging Markets: infectious diseases, vaccinations, cardiovascular disease, diabetes, women’s health and respiratory.
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here
